<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398356</url>
  </required_header>
  <id_info>
    <org_study_id>ST.C310.17.009</org_study_id>
    <nct_id>NCT03398356</nct_id>
  </id_info>
  <brief_title>Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.</brief_title>
  <official_title>The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wroclaw Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of different doses of metformin on the function of&#xD;
      endothelium in people with pre-diabetes. One group of the patients will receive metformin in&#xD;
      dose: 1500 mg, the second one will receive 3000 mg/day.&#xD;
&#xD;
      The parameters from healthy volunteers will be taken only at the study beginning to compare&#xD;
      the test results with the parameters from patients with pre-diabetes. This group will be not&#xD;
      treated with metformin (no intervention)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to exercise and diet, metformin is a medicine used to treat diabetes mellitus&#xD;
      (DM) and pre-diabetic (pre-DM) conditions. This drug improves insulin sensitivity in both&#xD;
      groups of patients (DM and pre-DM) and as a result gives a reduction in blood glucose.&#xD;
&#xD;
      However, studies also confirm the effect of metformin on the reduction of cardiovascular risk&#xD;
      in patients with diabetes (UKPDStudy), regardless of the hypoglycaemic effect.&#xD;
&#xD;
      The precise mechanism of action of the drug in this field is not clear. There is also no data&#xD;
      on whether similar effects apply to patients with pre-diabetes. Although we know that this&#xD;
      group of patients is also characterized by increased cardiovascular risk.&#xD;
&#xD;
      One of the most important substances that are involved in vasodilation is nitric oxide (NO).&#xD;
      Impairment of its secretion is an important signal of endothelial damage and is connected&#xD;
      with cardiovascular complications.&#xD;
&#xD;
      The impact of metformin on endothelial function in pre-diabetes patients is not known. We do&#xD;
      not know the effect of the drug dose and its different serum concentration on the secretion&#xD;
      of the dilators of the vessels, which are associated with endothelial function.&#xD;
&#xD;
      The study involves patients with pre-diabetes who meet the inclusion criteria, have no&#xD;
      contraindication to participate in the study (see exclusion criteria), and give their written&#xD;
      consent after reading &quot;Information for the patient&quot;.&#xD;
&#xD;
      The conditions (IFG, IGT) for participation in the study are confirmed by a diabetologist&#xD;
      (principal investigator ) based on fasting glucose and OGTT (oral glucose tolerance test)&#xD;
      with 75 mg of glucose.&#xD;
&#xD;
      Metformin will be given in an increasing dose in accordance with the test protocol.&#xD;
&#xD;
      After reaching a one-week treatment with a dose of 3 x 500 mg, patients will be assigned to&#xD;
      group A -a continuation of a dose of 3 x 500 and group B- increase dose to 3 x 1000mg.&#xD;
      Randomization depends on the identification number (ID). The patients with an even, second&#xD;
      number in the PESEL (identification number) will be randomized to the A group, the patients&#xD;
      with the second, odd number in the PESEL will be randomized to the group B. Here as an&#xD;
      example: PESEL: 60010102823-&quot; 0&quot; is as an even number so the patient will be randomized to&#xD;
      the group A; PESEL: 61010102823- &quot;1&quot; is an odd number- the patient will be randomized to the&#xD;
      group B. This PESEL number (ID) in Poland is given to every person shortly after birth and&#xD;
      the researchers have no influence on it.&#xD;
&#xD;
      In the final stage also patients from group B (metformin: 3 x 1000 mg), will back to the&#xD;
      treatment dose of metformin 3 x 500 mg- to show the relationship between the dose, serum&#xD;
      concentration of the metformin and its effect on the secretion of the measured substances.&#xD;
&#xD;
      The healthy volunteers will be not treated with metformin. Patients will be reminded by phone&#xD;
      about the increase in metformin dose as well as on control visits.&#xD;
&#xD;
      The lack of possible treatment with proper doses of metformin due to poor drug tolerance will&#xD;
      move the patient from group B to group A if such dose (3 x 500 mg) is well tolerated. The&#xD;
      patient will be excluded from the study if no compliance or lack of contact with the patient&#xD;
      will be recorded during the treatment period or if metformin dose: 3 x 500 mg will be&#xD;
      characterized with bad tolerance.&#xD;
&#xD;
      Information about: age, gender, BMI, cardiovascular risk factors, the current basic&#xD;
      lab-tests, and pharmacotherapy will be recorded.&#xD;
&#xD;
      The blood samples for: plasma metformin level and listed substances will be collected for&#xD;
      patients with pre-diabetes as described below (see diagram). The basic parameters as well as&#xD;
      NO indirect products concentrations will be assessed for healthy volunteers only once-at the&#xD;
      beginning of the study.&#xD;
&#xD;
      Test 1: NO(0) (indirect products) for patients before treatment start&#xD;
&#xD;
      3 weeks increasing dose of metformin to the final dose: 1500mg/day&#xD;
&#xD;
      3 x 500 mg (1500/day)- the dose is reached&#xD;
&#xD;
      3 weeks treatment 1500mg/day&#xD;
&#xD;
      Tests 2: NO1(1500) and metformin concentration&#xD;
&#xD;
      Randomization B:3 weeks increasing dose A: 6 weeks continuation with of metformin to the&#xD;
      final a dose 3 x 500 mg&#xD;
&#xD;
      dose 3 x 1000mg&#xD;
&#xD;
      3 x 1000mg (3000mg/day)- the dose is reached 3 weeks treatment 3000mg/day Tests 3: NO2(1000)&#xD;
      or NO3(500) and metformin concentration for both groups&#xD;
&#xD;
      3 weeks treatment 1500mg/day for both groups&#xD;
&#xD;
      Test 4: NO4 and metformin concentration&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      For statistical analysis, the Statistica 12 program will be used (StatSoft Polska Sp. z o.o.&#xD;
      www.statsoft.pl).&#xD;
&#xD;
      The cut-off point for statistical significance (p) was determined at 0.05. To determine the&#xD;
      statistical significance will be used tests compliant with the distribution of variables and&#xD;
      data character (Student's t-test, Mann-Whitney test, chi-square test, Kruskal-Wallis ANOVA&#xD;
      test). For analysis taking into account the duration of the study and determine the impact of&#xD;
      relevant variables to achieve the appropriate concentration of nitric oxide will be used Cox&#xD;
      proportional hazard regression. The goal of the optimal determination cut-off point for&#xD;
      predictors will use ROC curves. Logistic regression was used to determine the independent&#xD;
      predictors to obtain the desired concentration of nitric oxide. In order to determine the&#xD;
      correlation, it will be used correlation of order Spearman's rank correlation coefficient or&#xD;
      Pearson correlation coefficient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The group of patients taking the drug at the target dose of 3 x 1000 after 4 weeks returned to the dose of 3 x 500 mg. The group of patients taking the drug at the target dose 3 x 500 mg consequently had this dose during the whole study period.&#xD;
The basic parameters and biochemical parameters from healthy individuals at the beginning of the study were assessed to compare with patients with pre-diabetes. This group did not take the metformin and thus did not have further examination and lab-tests during the study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>At the beginning of the study, patients are assigned a number by a nurse and are assigned to group A or B according to ID. When analyzing the results, the researchers only knows the numbers of blood samples.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Levels of Metformin at Different Time Points</measure>
    <time_frame>6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
    <description>the serum concentration of the studied drug-metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of Arginine at Different Time Points</measure>
    <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
    <description>arginine serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of ADMA at Different Time Points</measure>
    <time_frame>before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
    <description>ADMA- asymmetric dimethylarginine-serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of SDMA at Different Time Points</measure>
    <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
    <description>SDMA-symmetric dimethylarginine-serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of Citrulline at Different Time Points</measure>
    <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
    <description>serum concentration of the citrulline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of DMA at Different Time Points</measure>
    <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
    <description>DMA- dimethylamine, serum concentration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Impaired Fasting Glucose (IFG)</condition>
  <condition>Impaired Glucose Tolerance (IGT)</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>metformin dose 3 x 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>metformin dose 3 x 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <other_name>Metformax</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Formetic</other_name>
    <other_name>Siofor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for treated groups ( A or B):&#xD;
&#xD;
          -  age: 40-65 years;&#xD;
&#xD;
          -  pre-diabetic status based on fasting plasma glucose (FPG) and / or OGTT;&#xD;
&#xD;
          -  without metformin before;&#xD;
&#xD;
          -  without ischemic heart disease in history;&#xD;
&#xD;
          -  without a stroke in a history;&#xD;
&#xD;
          -  without PAOD (peripheral arterial occlusive disease) in a history;&#xD;
&#xD;
          -  without active cancer in a history&#xD;
&#xD;
        Exclusion Criteria for treated groups (A or B):&#xD;
&#xD;
          -  age &lt;40 or &gt;65;&#xD;
&#xD;
          -  diabetes;&#xD;
&#xD;
          -  taking metformin before study;&#xD;
&#xD;
          -  active cancer;&#xD;
&#xD;
          -  history of macro-angiopathy (ischemic heart disease, stroke or TIA, PAOD);&#xD;
&#xD;
          -  serious gastrointestinal disease that may affect metformin tolerance;&#xD;
&#xD;
          -  renal failure with GFR&lt;45 ml/min/1.73m2;&#xD;
&#xD;
          -  alanin transaminase &gt; 3 x ULN&#xD;
&#xD;
        Inclusion criteria for healthy volunteers:&#xD;
&#xD;
          -  age: 40-65 years;&#xD;
&#xD;
          -  no carbo-hydrates disturbances (based on fasting plasma glucose (FPG) and/or OGTT);&#xD;
&#xD;
          -  without metformin before;&#xD;
&#xD;
          -  without ischemic heart disease in history;&#xD;
&#xD;
          -  without a stroke in a history;&#xD;
&#xD;
          -  without PAOD (peripheral arterial occlusive disease) in a history;&#xD;
&#xD;
          -  without active cancer in a history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edyta Sutkowska, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wroclaw Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NZOZ Nowy Dwór</name>
      <address>
        <city>Wroclaw</city>
        <state>Lower Silesia</state>
        <zip>54-438</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006 Jun;23(6):579-93.</citation>
    <PMID>16759299</PMID>
  </results_reference>
  <results_reference>
    <citation>Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 Aug;49(8):1711-21. Erratum in: Diabetologia. 2006 Nov;49(11):2816-8.</citation>
    <PMID>16802130</PMID>
  </results_reference>
  <results_reference>
    <citation>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558.</citation>
    <PMID>9742977</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamed S, Brenner B, Roguin A. Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2. Cardiovasc Res. 2011 Jul 1;91(1):9-15. doi: 10.1093/cvr/cvq412. Epub 2010 Dec 24. Review.</citation>
    <PMID>21186243</PMID>
  </results_reference>
  <results_reference>
    <citation>De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005 Jan;257(1):100-9.</citation>
    <PMID>15606381</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiśniewski J, Fleszar MG, Piechowicz J, Krzystek-Korpacka M, Chachaj A, Szuba A, Lorenc-Kukula K, Masłowski L, Witkiewicz W, Gamian A. A novel mass spectrometry-based method for simultaneous determination of asymmetric and symmetric dimethylarginine, l-arginine and l-citrulline optimized for LC-MS-TOF and LC-MS/MS. Biomed Chromatogr. 2017 Nov;31(11). doi: 10.1002/bmc.3994. Epub 2017 May 24.</citation>
    <PMID>28436051</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <results_first_submitted>June 19, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wroclaw Medical University</investigator_affiliation>
    <investigator_full_name>Edyta Sutkowska</investigator_full_name>
    <investigator_title>MD, PhD; The Head of the Department and Division of Medical Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>prediabetes</keyword>
  <keyword>impaired fasting glucose</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>metformin</keyword>
  <keyword>nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary outcome will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>the results will be available after the publication of the study</ipd_time_frame>
    <ipd_access_criteria>data will be available after giving permission by the Investigator</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03398356/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>control healthy volunteers, no intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Before Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0">only baseline parameters were taken, this group did not participate in the further part of the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>drug intolerance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After 6 Weeks of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0">control group- only initial parameters were assessed to compare, no follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0">control group- only initial parameters were assessed to compare, no follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post 6 Week Period Initial Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">two of the patients were moved from group B, because of intolerance of the higher dose of the drug</participants>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>After 12 Weeks of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0">control group- only initial parameters were assessed to compare, no follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0">control group- only initial parameters were assessed to compare, no follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>After 15 Weeks of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0">control group- only initial parameters were assessed to compare, no follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0">control group- only initial parameters were assessed to compare, no follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>group C was a comparator only for baseline parameters</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Patients with pre-diabetes; metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment with a final dose 3 x 500 mg, after 3 weeks of the titration Total treatment time: 15 weeks</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Patients with pre-diabetes, max metformin dose 3 x 1000 mg&#xD;
Metformin: for group B: 3 weeks metformin treatment with a dose 3 x 500 mg, after 3 weeks of the titration next: 3 weeks metformin treatment with a final dose 3 x 1000mg, after 3 weeks of the titration next: 3 weeks metformin treatment with a dose 3 x 500 mg. Total treatment time: 15 weeks</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>healthy volunteers</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.64" spread="8.85"/>
                    <measurement group_id="B2" value="55.73" spread="8.27"/>
                    <measurement group_id="B3" value="49.90" spread="8.37"/>
                    <measurement group_id="B4" value="51.97" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.49" spread="5.26"/>
                    <measurement group_id="B2" value="30.75" spread="4"/>
                    <measurement group_id="B3" value="26.99" spread="5.43"/>
                    <measurement group_id="B4" value="29.89" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.71" spread="13.74"/>
                    <measurement group_id="B2" value="92.36" spread="9.73"/>
                    <measurement group_id="B3" value="80.81" spread="20.64"/>
                    <measurement group_id="B4" value="90.52" spread="16.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.86" spread="0.18"/>
                    <measurement group_id="B2" value="0.89" spread="0.16"/>
                    <measurement group_id="B3" value="0.73" spread="0.03"/>
                    <measurement group_id="B4" value="0.85" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>alanin transaminase</title>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.13" spread="14.01"/>
                    <measurement group_id="B2" value="35.45" spread="20.51"/>
                    <measurement group_id="B3" value="19.11" spread="12.06"/>
                    <measurement group_id="B4" value="28.11" spread="16.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TCL- total cholesterol level</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207.21" spread="50.22"/>
                    <measurement group_id="B2" value="184.91" spread="34.19"/>
                    <measurement group_id="B3" value="201" spread="27.47"/>
                    <measurement group_id="B4" value="198.50" spread="39.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TG-triglicerydes</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.29" spread="62.77"/>
                    <measurement group_id="B2" value="136.82" spread="66.63"/>
                    <measurement group_id="B3" value="137.09" spread="49.20"/>
                    <measurement group_id="B4" value="135.53" spread="58.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL- high density lipoprotein</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.86" spread="12.07"/>
                    <measurement group_id="B2" value="50.73" spread="14.35"/>
                    <measurement group_id="B3" value="57.91" spread="16.82"/>
                    <measurement group_id="B4" value="52.58" spread="14.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-low density lipoprotein</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.29" spread="30.79"/>
                    <measurement group_id="B2" value="106.95" spread="23.78"/>
                    <measurement group_id="B3" value="115.70" spread="19.91"/>
                    <measurement group_id="B4" value="116.75" spread="26.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109.39" spread="11.13"/>
                    <measurement group_id="B2" value="107.23" spread="5.95"/>
                    <measurement group_id="B3" value="88.81" spread="4.44"/>
                    <measurement group_id="B4" value="102.44" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>liver steatosis</title>
          <description>assessed by ultrasonography as Yes or No</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>nicotinism</title>
          <description>active smoker- based on the patient's relation: Yes or No</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hypertension</title>
          <description>based on patient's relation or information from the medical-records</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>family history for DM</title>
          <description>based on the patient's relation: first-line relatives: Yes or No</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>arginine</title>
          <description>LC-MS/MS (liquid chromatography-mass spectrometry) technique</description>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.29" spread="28.15"/>
                    <measurement group_id="B2" value="110.37" spread="27.63"/>
                    <measurement group_id="B3" value="122.11" spread="27.96"/>
                    <measurement group_id="B4" value="115.48" spread="27.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADMA</title>
          <description>LC-MS/MS (liquid chromatography-mass spectrometry) technique</description>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.51" spread="0.09"/>
                    <measurement group_id="B2" value="0.53" spread="0.09"/>
                    <measurement group_id="B3" value="0.56" spread="0.10"/>
                    <measurement group_id="B4" value="0.53" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDMA</title>
          <description>LC-MS/MS (liquid chromatography-mass spectrometry) technique</description>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.39" spread="0.07"/>
                    <measurement group_id="B2" value="0.41" spread="0.10"/>
                    <measurement group_id="B3" value="0.42" spread="0.08"/>
                    <measurement group_id="B4" value="0.41" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DMA</title>
          <description>LC-MS/MS (liquid chromatography-mass spectrometry) technique</description>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.77" spread="0.71"/>
                    <measurement group_id="B2" value="1.74" spread="0.48"/>
                    <measurement group_id="B3" value="1.67" spread="0.40"/>
                    <measurement group_id="B4" value="1.73" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Citrulline</title>
          <description>LC-MS/MS (liquid chromatography-mass spectrometry) technique</description>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.10" spread="9.84"/>
                    <measurement group_id="B2" value="38.33" spread="7.49"/>
                    <measurement group_id="B3" value="36.45" spread="8.82"/>
                    <measurement group_id="B4" value="36.11" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ornithine</title>
          <description>LC-MS/MS (liquid chromatography-mass spectrometry) technique</description>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.77" spread="11.58"/>
                    <measurement group_id="B2" value="37.12" spread="15.71"/>
                    <measurement group_id="B3" value="35.57" spread="11.09"/>
                    <measurement group_id="B4" value="35.73" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Metformin at Different Time Points</title>
        <description>the serum concentration of the studied drug-metformin</description>
        <time_frame>6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
        <population>Group A and B- patients with pre-diabetes treated with different metformin dose (according to the information above as arm description) , group C- healthy volunteers, no metformin assessment as no treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>control healthy volunteers, no intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Metformin at Different Time Points</title>
          <description>the serum concentration of the studied drug-metformin</description>
          <population>Group A and B- patients with pre-diabetes treated with different metformin dose (according to the information above as arm description) , group C- healthy volunteers, no metformin assessment as no treatment</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="2.36"/>
                    <measurement group_id="O2" value="4.25" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="2.29"/>
                    <measurement group_id="O2" value="7.42" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="3.73"/>
                    <measurement group_id="O2" value="4.01" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Arginine at Different Time Points</title>
        <description>arginine serum concentration</description>
        <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
        <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>control healthy volunteers, no intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Arginine at Different Time Points</title>
          <description>arginine serum concentration</description>
          <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.18" spread="53.42"/>
                    <measurement group_id="O2" value="111.72" spread="36.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.72" spread="13.93"/>
                    <measurement group_id="O2" value="97.69" spread="38.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.72" spread="34.21"/>
                    <measurement group_id="O2" value="103.76" spread="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of ADMA at Different Time Points</title>
        <description>ADMA- asymmetric dimethylarginine-serum concentration</description>
        <time_frame>before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
        <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>control healthy volunteers, no intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of ADMA at Different Time Points</title>
          <description>ADMA- asymmetric dimethylarginine-serum concentration</description>
          <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.11"/>
                    <measurement group_id="O2" value="0.57" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.09"/>
                    <measurement group_id="O2" value="0.55" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.08"/>
                    <measurement group_id="O2" value="0.52" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of SDMA at Different Time Points</title>
        <description>SDMA-symmetric dimethylarginine-serum concentration</description>
        <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
        <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>control healthy volunteers, no intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of SDMA at Different Time Points</title>
          <description>SDMA-symmetric dimethylarginine-serum concentration</description>
          <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.08"/>
                    <measurement group_id="O2" value="0.45" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.08"/>
                    <measurement group_id="O2" value="0.42" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.07"/>
                    <measurement group_id="O2" value="0.39" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Citrulline at Different Time Points</title>
        <description>serum concentration of the citrulline</description>
        <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
        <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>control healthy volunteers, no intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Citrulline at Different Time Points</title>
          <description>serum concentration of the citrulline</description>
          <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.73" spread="6.66"/>
                    <measurement group_id="O2" value="28.08" spread="11.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.95" spread="9.48"/>
                    <measurement group_id="O2" value="27.01" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.93" spread="9.71"/>
                    <measurement group_id="O2" value="29.77" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of DMA at Different Time Points</title>
        <description>DMA- dimethylamine, serum concentration</description>
        <time_frame>Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start</time_frame>
        <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>control healthy volunteers, no intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of DMA at Different Time Points</title>
          <description>DMA- dimethylamine, serum concentration</description>
          <population>Groups A and B -patients with pre-diabetes treated with different dose of the metformin, group C- healthy volunteers, no metformin</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.31"/>
                    <measurement group_id="O2" value="2.07" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.28"/>
                    <measurement group_id="O2" value="1.89" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 weeks from the start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.34"/>
                    <measurement group_id="O2" value="1.84" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 weeks</time_frame>
      <desc>Other- important gastrointestinal side effects which did not allow the prescribed dose to be continued</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>metformin dose 3 x 500 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>metformin dose 3 x 1000 mg&#xD;
Metformin: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg&#xD;
for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>healthy volunteers, no intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>drug intolerance</sub_title>
                <description>the side effect which did not allow the prescribed dose to be continued</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We didn't differentiate pts according to sex or gender. Before the study was finished we assessed the correlation between metformin concentration and BMI/ body mass. It was prepared as an additional analysis based on 20 cases (not published yet).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Edyta Sutkowska</name_or_title>
      <organization>Wroclaw Medical University</organization>
      <phone>+48/503077016</phone>
      <email>edytasutkowska@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

